3013 Science Park Road
Suite 200
San Diego, CA 92121
United States
858 684 1300
https://www.gossamerbio.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 135
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Faheem Hasnain | Co-Founder, CEO, President & Chairman | 910,26k | N/D | 1958 |
Mr. Bryan Giraudo | COO & CFO | 708,09k | N/D | 1975 |
Mr. Robert P. Smith | Chief Commercial Officer | 135,79k | N/D | 1969 |
Mr. Christian Waage | Executive Vice President of Technical Operations & Administration | 583,16k | N/D | 1967 |
Mr. Jeff Boerneke | General Counsel & Secretary | N/D | N/D | N/D |
Ms. Deanna Weber | Senior Vice President of Human Resources | N/D | N/D | N/D |
Dr. Richard Aranda M.D. | Chief Medical Officer | 625,24k | N/D | 1961 |
Mr. Mario Orlando | Senior Vice President of Commercial New Product Planning | N/D | N/D | N/D |
Ms. Caryn L. Peterson | Executive Vice President of Regulatory Affairs | N/D | N/D | 1959 |
Mr. Matt Cravets | Senior Vice President of Biometrics | N/D | N/D | N/D |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Gossamer Bio, Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 10.